|Composition||Gliclazide 30,40,60 and 80 mg tablets|
|Indication||Type 2 Diabetes|
|Mechanism of Action||
Gliclazide stimulates insulin secretion from pancreatic β-cells, reduces insulin uptake and glucose output by the liver, and increases insulin sensitivity at peripheral target sites. It decreases microthrombosis by partial inhibition of platelet aggregation and adhesion, and by restoring fibrinolysis w/ an increase in tissue plasminogen activator (t-PA) activity.
Absorption: Readily absorbed from the GI tract. Bioavailability: 97%. Time to peak plasma concentration: 4-6 hr (immediate-release tab); approx 6 hr (modified-release tab).
Distribution: Plasma protein binding: Approx 94-95%.
Metabolism: Extensively hepatic via CYP2C9 and CYP2C19 isoenzymes converted to inactive metabolites.
Excretion: Via urine (60-70% as metabolites; <1% as unchanged drug) and faeces (10-20% as metabolites). Half-life: Approx 10-12 hr.
Hypoglycaemia, GI disturbances (e.g. diarrhoea, constipation, gastroenteritis, abdominal pain), HTN, angina, headache, dizziness, skin disorder, back pain, arthralgia, weakness, bronchitis, rhinitis, pharyngitis, upper resp infection, viral infection
Patient w/ G6PD deficiency. Patient exposed to stress (e.g. trauma, infection, surgery). Mild to moderate hepatic and renal impairment. Patient Counselling Adhere strictly to diabetic diet. Monitoring Parameters Monitor fasting blood glucose, glycosylated Hb, signs and symptoms of hypoglycaemia.
Adult: Take as directed. Titrate according to response.